83950 Oncoprotein her-2/neu
Pathology & Lab
Also known as: HER2/neu test, HER2 assay
Quantitative measurement of human epidermal growth factor receptor 2 (HER2/neu) oncoprotein in tissue or blood using immunoassay.
Clinical Context
Prognostic and predictive test for breast cancer determining eligibility for anti-HER2 therapy (trastuzumab). Approximately 20-25% of breast cancers are HER2-positive.
RVU Breakdown
| Work RVU | 0.00 |
| Practice Expense RVU | 0.00 |
| Malpractice RVU | 0.00 |
| Total RVU | 0.00 |
Specialties
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.